Lexicon plans to raise $95 million
This article was originally published in Scrip
Executive Summary
Lexicon Pharmaceuticals has announced plans to offer for sale $95 million of its common stock in an underwritten public offering. It could also sell up to $14.25 million worth of shares as an over-allotment option.